13F filer · CIK 1746488
Ponoi II Management, LLC
San Francisco, CA · filing since Q4 2020 · last filing Nov 14, 2022
Reported value
$38.3M
+$1.5M vs prior
Positions
4
New / sold out
0 / 0
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $0
Top-10 weight
100.0%
Biggest buys vs Q2 2022
No new or increased positions this quarter.
Biggest sells vs Q2 2022
No reduced or sold positions this quarter.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2022
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | NGM Biopharmaceuticals IncCOM | 1,298,908 | $17.0M | 44.41% |
| 2 | Revolution Medicines IncCOM | 685,011 | $13.5M | 35.31% |
| 3 | Nurix Therapeutics IncCOM | 327,123 | $4.3M | 11.14% |
| 4 | RAPT Therapeutics IncCOM | 145,401 | $3.5M | 9.14% |